All News

FDA approves orforglipron, a once-daily oral GLP‑1 for weight management, taken with food or coffee—simplifying obesity treatment.

The algorithm adds a new diabetes classification pathway and expands comorbidity-driven pharmacotherapy guidance, incorporating recent trial data on GLP-1 receptor agonists, SGLT2 inhibitors, and MASLD.

Phase 3 data show oral PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at 8 weeks vs oral nonstatins in high-risk patients.

New evidence suggests lowering LDL-C to 44 mg/dL with PCSK9 therapy may better protect high-risk patients with diabetes, aligning primary prevention targets with secondary prevention.

Phase 3b findings suggest that combining a GLP-1/GIP receptor agonist with IL-17 inhibition may improve both joint and metabolic outcomes in adults with psoriatic arthritis and obesity.

Once-weekly insulin makes injections simpler, boosts adherence, and lets clinics train patients fast—ideal for older adults.

Your daily dose of the clinical news you may have missed.

ACC 2026: A new secondary analysis of the VESALIUS-CV study shows evolocumab cuts heart attacks, strokes and deaths in high‑risk patients with type 2 diabetes.

The approval of Foundayo (orforglipron) marks a formulation milestone in obesity pharmacotherapy, offering a once-daily pill free of the fasting requirements that may complicate adherence.

Your daily dose of the clinical news you may have missed.

Which patients are most likely to benefit from once-weekly insulin? Early insights on insulin icodec for adults with type 2 diabetes, here.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

Your daily dose of the clinical news you may have missed.

From oral GLP-1s for obesity and T2D to a potential first new smoking cessation drug in 20 years, here are 5 FDA pipeline updates to put on your radar.

The FDA has approved Awiqli® (insulin icodec-abae), the first once-weekly basal insulin for adults with type 2 diabetes, reducing injections from 7 to 1 per week.

New 4-year data from the ADlong trial show lebrikizumab achieved EASI-75 in 94% of atopic dermatitis patients on once-monthly maintenance dosing.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.